2305629-50-7

Ubamatamab (REGN4018; 0.01-0.5 mg/kg; i.p; on days 6, 10, 13, 16, and 21) potently inhibits growth of intraperitoneal ovarian tumors^[1].
Ubamatamab (REGN4018; 0.01-1 mg/kg; i.p; once a week; total of five doses) shows minimal and transient increases in serum cytokines and C-reactive protein, with no overt toxicity^[1].